Real-World data on kidney drug finerenone in chinese patients

NCT ID NCT07124039

Completed Knowledge-focused Sponsor: Bayer Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This completed study analyzed electronic health records from over 6,500 patients in China who started taking finerenone for chronic kidney disease and type 2 diabetes. Researchers tracked kidney function, potassium levels, and side effects like high potassium. The goal was to see how the drug performs in everyday medical practice, not just in controlled trials.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Finerenone (Kerendia)
What this could lead to: If successful, this study could provide doctors with better information on how to safely use finerenone in everyday practice for patients with diabetic kidney disease.
What could go wrong: This is an observational study, not a controlled trial, so it cannot prove cause and effect. Results may not apply to patients outside of China.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC KIDNEY DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic kidney disease chronic renal failure syndrome diabetic kidney disease type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CHRONIC KIDNEY DISEASE TYPE 2 DIABETES MELLITUS

Contacts and locations

Locations

Inspur Tianjin Regional Electronic Health Records Database

Tianjin, Tianjin Municipality, 301799, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.